1. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa. (1st January 2021) Authors: Hansen, Ryan N.; Suh, Kangho; Serbin, Michael; Yonan, Chuck; Sullivan, Sean D. Journal: Journal of medical economics Issue: Volume 24:Number 1(2021) Page Start: 563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. (1st January 2021) Authors: Ganz, Michael L.; Chavan, Ameya; Dhanda, Rahul; Serbin, Michael; Yonan, Charles Journal: Journal of medical economics Issue: Volume 24:Number 1(2021) Page Start: 103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. In Reply to Xue W, Ribalov R, Zhou Z-Y, et al. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103–113. (1st January 2021) Authors: Serbin, Michael; Yonan, Charles; Ganz, Michael L. Journal: Journal of medical economics Issue: Volume 24:Number 1(2021) Page Start: 891 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗